Meiogenix (France) has signed with Bayer Crop Science (Germany) for use of their gene-editing platform, to try and ‘Unlock’ crop genetic diversity and improve food security.

meiogenix_spix_crop_sciences_bayer_food_security_agriculture_biotech_gene_engineering

Launched in 2011, this Parisian biotech was a spin-off of the Institut Curie and the French Agricultural Agency (INRA) after successfully raised funding.

ADVERTISEMENT

Now, under this non-exclusive agreement, Meiogenix will provide Bayer access to their SpiX technology and the research it has built over the years through different programs in rice, maize and wheat.

Meiogenix is developing complementary breakthrough technologies (such as SpiX) to increase the amount of meiotic recombination – an exchange of genetic material during cell division.

wheat_maize_rice_meiogenix_spix_bayer_crop_biotech_gene_meiotic_recombination_spo11

Meiogenix already has collaborations to apply SpiX in rice, maize and wheat. Model organisms such as Saccharomyces cerevisiae and Arabidopsis thaliana are also being used to further develop the platform (Source: Meiogenix)

SpiX is a fusion protein platform based on the research of Alain Nicolas at the Institut Curie, to amplify the amount of genetic diversity within plant species through natural breeding.

Nicolas and team fused an endonuclease enzyme responsible for initiating the meiotic recombination (Spo11) to a DNA binding domain (originally GAL4). This increased the frequency of gene recombination in ‘cold regions’ of the plant genome (which are typically more conserved).

meiogenix_spix_meiotic_recombination_biotech

SpiX technology is a fusion protein constituted by two domains. Spo11 (Recombination) introduces meiotic double-strain-breaks (DSBs), and therefore a source of variety within the genetic code.  (Source: Meiogenix)

This therefore ‘unlocks’ potential genetic variation from within the plants genome, helping to accelerate the introduction of new characteristics.

Originally achieved in Yeast, researchers on SpiX went on to use much more precise gene-editing domains than GAL4 to target the Spo11 protein, such as TALE, Zinc Fingers and even Cas9 (CRISPR).

Although financial terms were not disclosed in this case, the availability of funding for Crop sciences research is on the rise, demonstrating the urgency of this economic need.

meiogenix_bayer_crop_science_spix_agriculture_gene_technoology_food_biotech

Partners and collaborations on Meiogenix’ SpiX platform…

Just recently in Italy, €21M was dished out by the government as an incentive to research such gene technologies (like the cisgenic approach), which speed up natural processes and can help improve crop yields.

As the CEO and co-founder of Meiogenix, Giacomo Bastianelli, affirmed I personally believe that genetic technologies that mimic natural processes will contribute to producing food for generations to come.’

So Meiogenix appears to have an interesting technology on their hands, and it will be interesting to see who follows in Bayer’s footsteps.


Feature Image Credit: © Vladteodor (BigStock ID83444033)
Previous post

Allergan Signs Massive €3Bn Alzheimer's Deal with UK Biotech

Next post

Biotech of the Week: Activartis Immuno-Oncology in Vienna

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.